首页> 外文期刊>Clinical advances in hematology & oncology: H&O >Using ligands to target cancer cells.
【24h】

Using ligands to target cancer cells.

机译:使用配体靶向癌细胞。

获取原文
获取原文并翻译 | 示例
           

摘要

Nanoparticle (NP) carriers typically have a diameter less than 100 nm and can be developed from any number of organic or inorganic materials. Many different classes of NPs have been developed or are currently under development for medical applications. These include NPs that can carry drugs or an imaging modality or a combination thereof, and these NPs can be further engineered with targeting moieties for differential delivery of their payload in a cell- or tissue-specific manner. In this regard, therapeutic NP carriers allow for selective and preprogrammed biodistribution of drugs and control over the kinetic of drug release and duration of drug exposure at the target site. Challenges with modern drug therapy include the difficulty in optimizing the pharmaceutical and pharmacologic properties of drugs. Using conventional drug development approaches, it has always been difficult to create safe and efficacious drugs. The use of NP carriers can drastically facilitate the optimization of both pharmaceutical and pharmacologic properties of drugs (ie, solubility, stability, pharmacokinetics, biodistribution, elimination, efficacy, and toxicity), thus improving the odds of success in drug development.
机译:纳米粒子(NP)载体的直径通常小于100 nm,并且可以由多种有机或无机材料制成。已经开发出或正在开发许多不同类别的NP用于医学应用。这些包括可以携带药物或成像方式或其组合的NP,并且可以将这些NP进一步与靶向部分一起工程化,以以细胞或组织特异性方式差异递送其有效载荷。在这方面,治疗性NP载体允许药物的选择性和预编程生物分布,并控制药物释放的动力学和靶位点的药物暴露时间。现代药物疗法的挑战包括难以优化药物的药物和药理特性。使用常规的药物开发方法,一直很难生产安全有效的药物。 NP载体的使用可以极大地促进药物的药物和药理特性(即溶解性,稳定性,药代动力学,生物分布,消除,功效和毒性)的优化,从而提高了药物开发成功的几率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号